Christopher Hite
Known title: EVP & Chairman, PartneringCIK: 0001814238
Associated companies
Transaction History
| RPRX | ▼ Sell | Open Market | 96,073 | $5.6M | 9/22/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 3,927 | $231K | 9/22/2026 | View on chart |
| RPRX | ▼ Sell | Gift | 16,800 | $0 | 8/19/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 100,000 | $6.0M | 8/18/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 11,002 | $0 | 8/5/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 97,446 | $5.5M | 6/30/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 2,554 | $146K | 6/30/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 29,400 | $1.7M | 6/30/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 600 | $34K | 6/30/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 32,408 | $1.8M | 6/23/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 117,592 | $6.4M | 6/23/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 24,263 | $0 | 5/6/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 26,626 | $0 | 2/11/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 6,168 | $0 | 11/5/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 3,696 | $0 | 8/6/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 48,646 | $0 | 5/8/2025 | View on chart |
| RPRX | ▼ Sell | Other | 300,000 | $0 | 2/14/2025 | View on chart |
| RPRX | ▼ Sell | Other | 300,000 | $0 | 5/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.